Open AccessInfluence of Concomitant Polypharmacy on Docetaxel-induced Febrile Neutropenia
Author(s) -
Katsuya Makihara,
Yuka Shimeda,
Tomokazu Matsumura
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10018
Subject(s) - concomitant , cyp3a4 , docetaxel , polypharmacy , febrile neutropenia , neutropenia , medicine , pharmacology , confidence interval , risk factor , gastroenterology , cancer , chemotherapy , cytochrome p450 , metabolism
Docetaxel (DTX) is metabolized by liver cytochromes P450 (CYP) 3A4 (CYP3A4) and 3A5 (CYP3A5) CYP3A4 activity is considered the main factor affecting the effectiveness in DTX clearance. We, therefore, explored the association between DTX-induced febrile neutropenia (FN) and concomitant polypharmacy involving CYP3A4 inhibitors in cancer patients.